Autolus Therapeutics (AUTL) Profit After Tax (2017 - 2025)

Autolus Therapeutics (AUTL) has reported Profit After Tax for 9 consecutive years, with -$90.3 million the latest figure, recorded in Q4 2025.

• Quarterly Profit After Tax fell 225.58% year-over-year to -$90.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$293.3 million (down 32.82% YoY) and the FY2025 annual result came in at -$287.5 million, down 30.2% from the prior year.
• Profit After Tax slipped to -$90.3 million in Q4 2025 per AUTL's latest filing, from -$84.9 million in the prior quarter.
• Over the last five years, Profit After Tax for AUTL reached as high as -$18.3 million in Q4 2022 and fell as low as -$90.3 million in Q4 2025.
• A 5-year average of -$52.8 million and a median of -$49.8 million in 2023 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2023 — Profit After Tax plunged 322.14% — and 2024, when it jumped 64.06%.
• Year by year, Profit After Tax stood at -$40.7 million in 2021, then jumped by 55.1% to -$18.3 million in 2022, then tumbled by 322.14% to -$77.2 million in 2023, then soared by 64.06% to -$27.7 million in 2024, then slumped by 225.58% to -$90.3 million in 2025.
• According to Business Quant data, Profit After Tax over the past three periods registered -$90.3 million, -$84.9 million, and -$47.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.